Last updated on September 2018

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

Brief description of study

The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.

Clinical Study Identifier: NCT02936037

Contact Investigators or Research Sites near you

Start Over

Mária Sátori, MD

Valeomed Kft
Esztergom, Hungary